CRTX - Cortexyme And The Gingipain Hypothesis Of Alzheimer's Disease

• Cortexyme has a unique hypothesis- that Alzheimer’s disease (AD) is caused by a neurological infection with P. gingivalis.
• There is a surprising amount of data generated by the company and independent labs supporting this hypothesis.
• The stock will likely soar if the GAIN trial meets its endpoints or fall dramatically if it does not. Investors should expect top line data in the next few weeks.
• Investors have a fall back indication in periodontal disease, where atuzaginstat has a high likelihood of showing efficacy and which is estimated to be a $2B commercial opportunity.

For further details see: